News / New publications

Research

We work together for a better translational approach, from basic to clinical science

  • Read more

Core facilities

Our advanced core facilities offer excellent opportunities

  • Read more

Recruitment

We welcome the best research talents from Norway and the rest of the world

  • Read more

Archives IEMR

  • Publications
  • News archive
  • Visual profile

About IEMR

  • About
  • Funding
  • Collaborations
  • Staff

Contact IEMR

  • Contact
  • Group leaders
  • Leadership
  • Safety representative (VO)

The extracellular matrix protein ‘ADAMTSL3’ is crucial for preserving cardiac structure and function in heart failure

Karoline B Rypdal, A Olav Melleby, Emma L Robinson, Jia Li, Sheryl Palmero, Deborah E Seifert, Daniel Martin, Catelyn Clark, Begoña López, Kristine Andreassen, Christen P Dahl, Ivar Sjaastad, Theis Tønnessen, Mathis K Stokke, William E Louch, Arantxa González, Stephane Heymans, Geir Christensen, Suneel S Apte, Ida G Lunde

ADAMTSL3 knock-out mice develop cardiac dysfunction and dilatation with increased TGFβ signalling after pressure overload

—

 

In our latest publication in Communications Biology, we reveal an essential role of ADAMTSL3, an extracellular protein of unknown function, in maintaining cardiac structural and functional integrity in the failing heart. By regulating a central heart failure signalling pathway, the TGFβ mediated activation of cardiac fibroblasts, ADAMTSL3 emerges as a potential therapeutic target for this deadly syndrome.

During heart failure progression the myocardium remodels to counteract the harmful stimuli. The extracellular matrix in-between cardiac muscle cells is crucial for maintaining cardiac structural and functional integrity, and an integral part of the remodelling response. In heart failure, cardiac fibroblasts are activated by the signalling molecule ‘transforming growth factor (TGF)β’, and transdifferentiate into highly proliferating and matrix-producing ‘myofibroblasts’, which drives pathological cardiac fibrosis. TGFβ thus represents an attractive therapeutic target, however, direct TGFβ inhibition is limited by adverse effects, warranting a better understanding of TGFβ regulation in the failing heart. In the present study, the role of the matrix glycoprotein ADAMTSL3 in heart failure was investigated through generation of a Adamtsl3 knock-out mouse. Importantly, the investigators discovered that the knock-out mice develop contractile dysfunction and cardiac dilatation, with high mortality, after aortic constriction, showing that ADAMTSL3 plays a crucial role in the failing heart. Molecular analysis revealed increased TGFβ activity and presence of myofibroblasts in the knock-outs, with increased levels of insoluble collagen, indicating a stiffer extracellular matrix. ADAMTSL3 was subsequently confirmed to inhibit TGFβ activity, myofibroblast differentiation, and extracellular matrix production in cultured human cardiac fibroblasts.

The study identifies ADAMTSL3 as an important part of the cardiac extracellular matrix, with an essential role in preserving cardiac function in the failing heart. As a negative regulator of the pro-fibrotic driver TGFβ, ADAMTSL3 may hold therapeutic potential for heart failure patients, and future investigations will reveal whether ADAMTSL3 has beneficial effects in the failing heart.

PMID: 36539599 PMCID: PMC9767913 DOI: 10.1038/s42003-022-04361-1

Karoline Bjarnesdatter Rypdal

Postdoctoral fellow

  • View profile

Ida Gjervold Lunde

Researcher

  • View profile

Institute for Experimental Medical Research

Oslo University Hospital, Ullevål

PB 4956 Nydalen

NO-0424 Oslo

Norway

  • Research
  • Core facilities
  • Recruitment
  • Publications
  • News archive
  • Visual profile
  • About
  • Funding
  • Collaborations
  • Staff
  • Contact
  • Group leaders
  • Leadership
  • Safety representative (VO)